Elucidating Hepatic Metabolism in Non-alcoholic Fatty Liver Disease

Enrolling by invitationOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2030

Conditions
Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
DIAGNOSTIC_TEST

Ketoisocaproic acid breath test

13C-alpha-ketoisocaproic acid breath test to estimate hepatic mitochondrial reductive stress (1 mg/kg body weight; oral dose; study duration 390 min)

DIAGNOSTIC_TEST

Ammonium Chloride

15N-ammonium chloride stable isotope test to estimate ureagenesis (20 mg/kg body weight; oral dose; study duration 390 min)

DIAGNOSTIC_TEST

Bicarbonate de sodium

13C-bicarbonate breath test to estimate body bicarbonate pool size and gastric emptying (0.5 mg/kg body weight; oral dose; study duration 390 min)

DIAGNOSTIC_TEST

Deuterated Water

Deuterated water stable isotope test to estimate hepatic de novo lipogenesis and gluconeogenesis (3 g/kg body water; oral dose; duration: overnight)

DIAGNOSTIC_TEST

Oral Glucose Tolerance Test

A standard 2-hour 75-gram oral glucose tolerance test to assess glucose tolerance and whole body metabolism

Trial Locations (1)

Unknown

Helsinki Central University Hospital, Helsinki

All Listed Sponsors
lead

Helsinki University Central Hospital

OTHER